Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Iparomlimab and Tuvonralimab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable Stage III-N2b Non-Small Cell Lung Cancer

NCT07538193 is registered in ClinicalTrials.gov with Tang-Du Hospital as lead sponsor.

NCT NCT07538193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07538193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Iparomlimab and Tuvonralimab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable Stage III-N2b Non-Small Cell Lung Cancer
Lead sponsor
Tang-Du Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
December 31, 2029
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung (nsclc), lymphatic metastasis, neoplasm staging